Related Experiment Videos
RF hyperthermia array modelling; validation by means of measured EM-field distributions
1Academic Medical Center, Department of Radiotherapy, Amsterdam, The Netherlands. wiersmaj@amc.uva.nl
Summary
Hyperthermia treatment simulations using the Weak Form Conjugate Gradient FFT method accurately predict electromagnetic fields but are insufficient for individual patient quantitative dosimetry. Qualitative dosimetry is suitable for retrospective analysis and planning. Keywords: hyperthermia, simulation, dosimetry, electromagnetic fields.
Area of Science:
- Medical Physics
- Computational Electromagnetics
Background:
- Accurate hyperthermia treatment simulation is crucial for prospective treatment planning and patient-specific dosimetry.
- The accuracy depends on both the numerical simulation method and the description of the hyperthermia system.
Purpose of the Study:
- To investigate the accuracy of the numerical description of the AMC-4 waveguide phased array hyperthermia system using the Weak Form Conjugate Gradient FFT method.
- To compare simulated and measured electromagnetic (EM) field data for validation.
Main Methods:
- Analysis of an analytically solvable problem to determine numerical method accuracy.
- Comparison of simulated and measured EM-field amplitude and phase for the AMC-4 system.
- Investigated four setups varying bolus size and number of waveguides on a phantom.
Main Results:
- The Weak Formulation of the Conjugate Gradient FFT method accurately predicts EM-fields for the AMC-4 system, including effects of bolus size variations.
- Simulated and measured EM-field distributions revealed the planning system's insufficiency for quantitative Specific Absorption Rate (SAR) dosimetry in individual patients.
Conclusions:
- The numerical description and simulation method are capable of qualitative SAR dosimetry for retrospective analysis or identifying potential problem areas.
- Prospective applications include qualitative planning, determining optimal amplitude/phase settings, and evaluating new hyperthermia devices.